Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Buys 9,230 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson bought 9,230 shares of Sensei Biotherapeutics stock in a transaction dated Tuesday, June 23rd. The stock was purchased at an average cost of $24.36 per share, with a total value of $224,842.80. Following the completion of the acquisition, the chief financial officer directly owned 17,413 shares in the company, valued at approximately $424,180.68. The trade was a 112.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Sensei Biotherapeutics Price Performance

Shares of NASDAQ FTH opened at $24.54 on Thursday. Sensei Biotherapeutics, Inc. has a 52-week low of $6.32 and a 52-week high of $36.76.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: CEO Anand Kiran Parikh bought 2,806 shares at $19.76 each, signaling confidence in Sensei Biotherapeutics’ outlook. CEO purchase SEC filing
• Positive Sentiment: CFO Brian C. Stephenson bought 9,230 shares at $24.36 each, a larger insider purchase that can be viewed as a strong vote of confidence from management. CFO purchase SEC filing
• Positive Sentiment: HC Wainwright reiterated a Buy rating and $60 price target, while lifting forecasts across multiple future periods, reinforcing a bullish long-term view of the stock. HC Wainwright research note
• Neutral Sentiment: HC Wainwright’s estimates still call for losses over the next several quarters and years, so the outlook remains highly speculative and dependent on future clinical or operational progress.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on FTH. HC Wainwright assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday. They set a “buy” rating and a $60.00 target price on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Finally, Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and an average price target of $60.00.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.